Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Developing Saccharomyces boulardii to deliver targeted therapeutic interventions to the gut

FY 2022-23

Summary
Crohn’s disease (CD) affects 135,000 Canadians and is characterized by chronic inflammation in the gut. A key contributor to this inflammation is the presence of an Escherichia coli (E. coli) strain known as adherent-invasive E. coli (AIEC). These AIEC invade into gut tissue which activates the immune system, leading to further inflammation and increased disease severity. While up to 63% of CD patients possess AIEC, treating AIEC infections is complex because the bacteria are multi-drug resistant. Moreover, antibiotics target other gut bacteria, which creates a less competitive niche that allows for increased AIEC proliferation. To address these challenges, our lab is developing alternative methods that can deliver site-specific therapeutics to target AIEC infections in CD patients. I am developing Saccharomyces boulardii yeast strains that express and deliver microcins against AIEC in the gut. Microcins are bacteria-derived proteins with antimicrobial properties. S. boulardii was selected as an expression system for microcin delivery because it has probiotic properties that support gut health. We have engineered S. boulardii to produce four microcins: plantaricin, H47, microcin M, and pediocin PA-1. We hypothesize that microcin-expressing S. boulardii will reduce AIEC levels. Several microcins have been shown to target AIEC in mice, and their expression by probiotic yeast will limit off-target effects on other microbes to prevent further AIEC growth. I aim to (i) study the activity of each microcin against AIEC in cell-based experiments, (ii) investigate whether microcin-expressing S. boulardii can reduce AIEC levels in mice, and (iii) investigate whether yeast-expressed microcins can re-sensitize AIEC to antibiotics that are commonly prescribed for CD patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486360
Name
Iacobucci Katarina R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing Saccharomyces boulardii to deliver targeted therapeutic interventions to the gut
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adherent-Invasive Escherichia Coli (Aiec); Antimicrobial Peptides; Crohn'S Disease; Microcins; Murine Model; Pathobiont; Probiotic; Prophylactic; Saccharomyces Boulardii; Treatment
Abstract
Crohn’s disease (CD) affects 135,000 Canadians and is characterized by chronic inflammation in the gut. A key contributor to this inflammation is the presence of an Escherichia coli (E. coli) strain known as adherent-invasive E. coli (AIEC). These AIEC invade into gut tissue which activates the immune system, leading to further inflammation and increased disease severity. While up to 63% of CD patients possess AIEC, treating AIEC infections is complex because the bacteria are multi-drug resistant. Moreover, antibiotics target other gut bacteria, which creates a less competitive niche that allows for increased AIEC proliferation. To address these challenges, our lab is developing alternative methods that can deliver site-specific therapeutics to target AIEC infections in CD patients. I am developing Saccharomyces boulardii yeast strains that express and deliver microcins against AIEC in the gut. Microcins are bacteria-derived proteins with antimicrobial properties. S. boulardii was selected as an expression system for microcin delivery because it has probiotic properties that support gut health. We have engineered S. boulardii to produce four microcins: plantaricin, H47, microcin M, and pediocin PA-1. We hypothesize that microcin-expressing S. boulardii will reduce AIEC levels. Several microcins have been shown to target AIEC in mice, and their expression by probiotic yeast will limit off-target effects on other microbes to prevent further AIEC growth. I aim to (i) study the activity of each microcin against AIEC in cell-based experiments, (ii) investigate whether microcin-expressing S. boulardii can reduce AIEC levels in mice, and (iii) investigate whether yeast-expressed microcins can re-sensitize AIEC to antibiotics that are commonly prescribed for CD patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Iacobucci, Katarina R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~